The company's flagship product is an implantable sensor that continuously measures glucose levels and a transmitter that sends this information at regular intervals.

The majority of its sales, 73.6%, are generated in the United States, and the company employs around 9550 people.

DexCom's sales are divided mainly between distributors (85.46%) and direct sales (14.54%), with a significant presence in the United States (72.48%) and internationally (27.52%).

It has enjoyed impressive growth in recent years, with a steady increase in sales from $1,476 million in 2019 to $3,622 million in 2023. EBITDA has followed a similar trajectory, increasing from $210 million in 2019 to $1,015 million in 2023.

The company's profitability also improved, with net margin rising from 6.85% in 2019 to 14.9% in 2023. DexCom's valuation has fluctuated, with market capitalization peaking in 2021 at $52,042 million before stabilizing at $47,945 million in 2023.

For 2024, DexCom forecasts organic sales growth of 16% to 21%, with an operating margin that should continue to expand around 20% and an adjusted EBITDA margin of 29%. These forecasts are underpinned by the expansion of access to CGM technology, both in the United States and internationally, and by the launch of new products such as Stelo.

DexCom expands access to glucose monitoring and reinforces its leadership

The company recently unveiled promising clinical data reinforcing the effectiveness of its CGM systems in diabetes management.

These results will be presented at the 17th International Conference on Advanced Technologies and Treatments for Diabetes in Florence. DexCom's G7 sensor, which will soon connect directly to the Apple Watch, has been launched in 16 new markets since ATTD 2023, while the Dexcom ONE+ is already available in eight markets.

These advances testify to DexCom's commitment to improving access and the user experience of its products.

Game-changing clinical evidence

Studies show that the use of DexCom CGM systems, in combination with automated insulin pumps, significantly reduces the risk of severe hypoglycemia and diabetic ketoacidosis. Data from the longest prospective study show that improvements in glycemic results can be maintained over two years by using the AID system with DexCom G6.

DexCom also announced a study linking the use of CGM to reduced mortality in people with type 1 and type 2 diabetes.

In addition, a new global analysis showed a significant reduction in HbA1c in people managing their type 2 diabetes with GLP1 and using a CGM sensor.

Stelo by Dexcom: a revolution available without a prescription

In a major breakthrough, the FDA has approved Stelo, the first over-the-counter glucose biosensor. This innovation paves the way for more autonomous, simplified management of type 2 diabetes for around 25 million Americans.

Stelo, which will be available online from summer 2024, promises to improve patients' quality of life by providing real-time glucose measurements directly on their smartphone.

With this authorization, DexCom confirms its position as a pioneer in the field of connected healthcare systems.

The company's advances in CGM and convincing clinical results underline the importance of these technologies in the effective management of diabetes. DexCom's increased accessibility and strategic partnerships with other players in the medical sector reinforce its leading role in improving care for diabetic patients worldwide.